Effect of Rosuvastatin Therapy on HDL2 Level

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT02593487

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT02593487
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02593487. Randomized; single masking; primary purpose prevention. Start 2015-11 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Rosuvastatin Therapy on HDL2 Level
Condition
Hyperlipemia
Condition
Coronary Heart Disease
Intervention (Drug)
Rosuvastatin 10mg/d group
Intervention (Drug)
Rosuvastatin 20mg/d group
Lead sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02593487
Content hash
65867dc09fb35ea6726f429cdfd6255e5c25dc24ef5063ad0797548ee9a2879e